Acesion Pharma
Major Drugs - N/A, N/A, DK
Acesion Pharma Details
Acesion Pharma is a Danish biotech company founded in 2011 by Ulrik Sørensen and Morten Grunnet. Current investors include Wellcome Trust (UK), Novo Holdings and Broadview Ventures (US). Acesion has received two substantial awards from the Wellcome Trust, an SDDI Award in 2013 and in 2016 a Translational Award.Acesion Pharma is aiming for developing more efficacious and safer drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. AF is associated with impaired quality of life, increased rate of hospitalisation, and increased risk of stroke and death. It is recognised that existing drug therapies only have a limited effect and are often followed by risks of serious adverse events. Therefore, there is a high unmet need for better drugs for the medical treatment of AF. The scientific foundation of Acesion Pharma is the novel concept of treating AF by inhibiting the so-called SK channels. These are ion channels present in the heart where they are relevant for regulating the cardiac rhythm. Blocking this ion channel with a selective drug molecule constitutes a novel and promising target for developing improved treatment of AF.
Acesion Pharma Technologies
Email Providers
Outlook
Load Balancers
Apache
Fonts
Google Font API
Tag Management
Google Tag Manager
Other
Mobile Friendly